• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心脏再同步治疗起搏器的设备运行时间和成本 - 一项健康索赔数据分析。

Device runtime and costs of cardiac resynchronization therapy pacemakers - a health claims data analysis.

机构信息

Institute of Social Medicine and Epidemiology, University of Lübeck, Germany.

Heart Center Leipzig, University of Leipzig, Germany.

出版信息

Ger Med Sci. 2022 Mar 4;20:Doc02. doi: 10.3205/000304. eCollection 2022.

DOI:10.3205/000304
PMID:35465639
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9006313/
Abstract

This study investigates the runtime and costs of biventricular defibrillators (CRT-D) and biventricular pacemakers (CRT-P). Accurate estimates of cardiac resynchronization therapy (CRT) device runtime across all manufactures are rare, especially for CRT-P. Health claims data of a large nationwide German health insurance was used to analyze CRT device runtime. We defined device runtime as the time between the date of implantation and the date of generator change or removal. The median costs for implantation, change, and removal of a CRT device were calculated accordingly. In total, the data set comprises 17,826 patients. A total of 4,296 complete runtimes for CRT-D devices and 429 complete runtimes for CRT-P devices were observed. Median device runtime was 6.04 years for CRT-D devices and 8.16 years for CRT-P devices (log-rank test p<0.0001). The median cost of implantation for a CRT-D device was 14,270 EUR, and for a CRT-P device 9,349 EUR. Compared to CRT-P devices, CRT-D devices had a significantly shorter device runtime of about two years. Moreover, CRT-D devices were associated with higher cost. The study provides important findings that can be utilized by cost-effectiveness analyses.

摘要

这项研究调查了双心室除颤器(CRT-D)和双心室起搏器(CRT-P)的运行时间和成本。准确估计所有制造商的心脏再同步治疗(CRT)设备的运行时间非常罕见,尤其是对于 CRT-P。使用大型全国性德国健康保险的健康索赔数据来分析 CRT 设备的运行时间。我们将设备运行时间定义为植入日期和发电机更换或移除日期之间的时间。相应地计算了 CRT 设备植入、更换和移除的中位数成本。 数据集共包含 17826 名患者。共观察到 4296 个 CRT-D 设备的完整运行时间和 429 个 CRT-P 设备的完整运行时间。CRT-D 设备的中位设备运行时间为 6.04 年,CRT-P 设备的中位设备运行时间为 8.16 年(对数秩检验 p<0.0001)。CRT-D 设备植入的中位数成本为 14270 欧元,而 CRT-P 设备为 9349 欧元。 与 CRT-P 设备相比,CRT-D 设备的设备运行时间明显缩短了约两年。此外,CRT-D 设备的成本更高。该研究提供了重要的发现,可以为成本效益分析提供依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2816/9006313/45a13bd9a8f0/GMS-20-02-g-004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2816/9006313/62c207566a4d/GMS-20-02-t-001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2816/9006313/2c1d81b3b41f/GMS-20-02-g-001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2816/9006313/f2c34be77184/GMS-20-02-g-002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2816/9006313/7373468f4112/GMS-20-02-g-003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2816/9006313/45a13bd9a8f0/GMS-20-02-g-004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2816/9006313/62c207566a4d/GMS-20-02-t-001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2816/9006313/2c1d81b3b41f/GMS-20-02-g-001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2816/9006313/f2c34be77184/GMS-20-02-g-002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2816/9006313/7373468f4112/GMS-20-02-g-003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2816/9006313/45a13bd9a8f0/GMS-20-02-g-004.jpg

相似文献

1
Device runtime and costs of cardiac resynchronization therapy pacemakers - a health claims data analysis.心脏再同步治疗起搏器的设备运行时间和成本 - 一项健康索赔数据分析。
Ger Med Sci. 2022 Mar 4;20:Doc02. doi: 10.3205/000304. eCollection 2022.
2
Economic Considerations of Cardiovascular Implantable Electronic Devices for The Treatment of Heart Failure.心力衰竭治疗用心血管植入式电子设备的经济学考虑。
Curr Heart Fail Rep. 2024 Jun;21(3):186-193. doi: 10.1007/s11897-024-00664-y. Epub 2024 Apr 25.
3
Economic Value and Cost-Effectiveness of Cardiac Resynchronization Therapy Among Patients With Mild Heart Failure: Projections From the REVERSE Long-Term Follow-Up.轻度心力衰竭患者心脏再同步治疗的经济价值和成本效益:REVERSE 长期随访预测结果。
JACC Heart Fail. 2017 Mar;5(3):204-212. doi: 10.1016/j.jchf.2016.10.014. Epub 2017 Jan 11.
4
Survival in Women Versus Men Following Implantation of Pacemakers, Defibrillators, and Cardiac Resynchronization Therapy Devices in a Large, Nationwide Cohort.在一个大型全国队列中,植入起搏器、除颤器和心脏再同步治疗设备后女性与男性的生存率比较
J Am Heart Assoc. 2017 May 10;6(5):e005031. doi: 10.1161/JAHA.116.005031.
5
The economic impact of battery longevity in implantable cardioverter-defibrillators for cardiac resynchronization therapy: the hospital and healthcare system perspectives.植入式心脏再同步治疗除颤器中电池寿命的经济影响:医院和医疗保健系统的观点。
Europace. 2017 Aug 1;19(8):1349-1356. doi: 10.1093/europace/euw176.
6
Remote Monitoring of Implantable Cardioverter-Defibrillators, Cardiac Resynchronization Therapy and Permanent Pacemakers: A Health Technology Assessment.植入式心脏复律除颤器、心脏再同步治疗及永久性起搏器的远程监测:一项卫生技术评估
Ont Health Technol Assess Ser. 2018 Oct 24;18(7):1-199. eCollection 2018.
7
Longevity of implantable cardioverter-defibrillators for cardiac resynchronization therapy in current clinical practice: an analysis according to influencing factors, device generation, and manufacturer.当前临床实践中用于心脏再同步治疗的植入式心脏复律除颤器的使用寿命:根据影响因素、设备代次和制造商进行的分析
Europace. 2015 Aug;17(8):1251-8. doi: 10.1093/europace/euv109. Epub 2015 May 14.
8
Survival of patients undergoing cardiac resynchronization therapy with or without defibrillator: the RESET-CRT project.接受心脏再同步治疗(有或无除颤器)患者的生存情况:RESET-CRT 项目。
Eur Heart J. 2022 Jul 14;43(27):2591-2599. doi: 10.1093/eurheartj/ehac053.
9
Battery drain in daily practice and medium-term projections on longevity of cardioverter-defibrillators: an analysis from a remote monitoring database.日常实践中的电池消耗及心脏复律除颤器寿命的中期预测:来自远程监测数据库的分析
Europace. 2016 Sep;18(9):1366-73. doi: 10.1093/europace/euv436. Epub 2016 Feb 3.
10
Battery longevity from cardiac resynchronization therapy defibrillators: differences between manufacturers and discrepancies with published product performance reports.心脏再同步治疗除颤器的电池寿命:制造商之间的差异以及与已发表的产品性能报告的不符之处。
Europace. 2017 Mar 1;19(3):421-424. doi: 10.1093/europace/euw044.

引用本文的文献

1
A long-term cost-effectiveness analysis of cardiac resynchronisation therapy with or without defibrillator based on health claims data.基于健康声明数据的心脏再同步治疗(无论是否配备除颤器)的长期成本效益分析
Cost Eff Resour Alloc. 2022 Sep 2;20(1):48. doi: 10.1186/s12962-022-00384-x.

本文引用的文献

1
Reliability and longevity of implantable defibrillators.植入式除颤器的可靠性和寿命。
J Interv Card Electrophysiol. 2021 Dec;62(3):507-518. doi: 10.1007/s10840-020-00920-w. Epub 2021 Jan 2.
2
Editor's Choice - Comorbidity Patterns Among Patients with Peripheral Arterial Occlusive Disease in Germany: A Trend Analysis of Health Insurance Claims Data.编辑精选 - 德国外周动脉阻塞性疾病患者的合并症模式:基于健康保险索赔数据的趋势分析。
Eur J Vasc Endovasc Surg. 2020 Jan;59(1):59-66. doi: 10.1016/j.ejvs.2019.08.006. Epub 2019 Nov 16.
3
Incidence of device-related infection in 97 750 patients: clinical data from the complete Danish device-cohort (1982-2018).
97750 例患者中器械相关感染的发生率:来自丹麦完整器械队列(1982-2018 年)的临床数据。
Eur Heart J. 2019 Jun 14;40(23):1862-1869. doi: 10.1093/eurheartj/ehz316.
4
Device complications with addition of defibrillation to cardiac resynchronisation therapy for primary prevention.除颤在心脏再同步治疗一级预防中的器械并发症。
Heart. 2018 Sep;104(18):1529-1535. doi: 10.1136/heartjnl-2017-312546. Epub 2018 Mar 14.
5
Effect of battery longevity on costs and health outcomes associated with cardiac implantable electronic devices: a Markov model-based Monte Carlo simulation.电池寿命对心脏植入式电子设备相关成本和健康结果的影响:基于马尔可夫模型的蒙特卡罗模拟
J Interv Card Electrophysiol. 2017 Nov;50(2):149-158. doi: 10.1007/s10840-017-0289-8. Epub 2017 Nov 6.
6
Utilization and in-hospital complications of cardiac resynchronization therapy: trends in the United States from 2003 to 2013.心脏再同步治疗的应用和院内并发症:2003 年至 2013 年美国的趋势。
Eur Heart J. 2017 Jul 14;38(27):2122-2128. doi: 10.1093/eurheartj/ehx100.
7
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.2016欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南:欧洲心脏病学会(ESC)急性和慢性心力衰竭诊断与治疗工作组编写,欧洲心脏病学会心力衰竭协会(HFA)提供特别贡献。
Eur Heart J. 2016 Jul 14;37(27):2129-2200. doi: 10.1093/eurheartj/ehw128. Epub 2016 May 20.
8
Device Longevity in a Contemporary Cohort of ICD/CRT-D Patients Undergoing Device Replacement.当代接受设备更换的植入式心脏复律除颤器/心脏再同步化治疗除颤器(ICD/CRT-D)患者队列中的设备使用寿命
J Cardiovasc Electrophysiol. 2016 Jul;27(7):840-5. doi: 10.1111/jce.12990. Epub 2016 Jun 17.
9
Battery longevity from cardiac resynchronization therapy defibrillators: differences between manufacturers and discrepancies with published product performance reports.心脏再同步治疗除颤器的电池寿命:制造商之间的差异以及与已发表的产品性能报告的不符之处。
Europace. 2017 Mar 1;19(3):421-424. doi: 10.1093/europace/euw044.
10
A review of economic evaluation models for cardiac resynchronization therapy with implantable cardioverter defibrillators in patients with heart failure.心力衰竭患者植入式心脏复律除颤器心脏再同步治疗的经济评估模型综述
Eur J Health Econ. 2016 Dec;17(9):1159-1172. doi: 10.1007/s10198-015-0752-3. Epub 2016 Jan 4.